Potential effects of valproate and oxcarbazepine on growth velocity and bone metabolism in epileptic children- a medical center experience

  • Chien Ming Lin (Contributor)
  • Hueng Chuen Fan (Contributor)
  • Tsu-Yi Chao (Contributor)
  • Der Ming Chu (Contributor)
  • Chi Chieh Lai (Contributor)
  • Chih Chien Wang (Contributor)
  • S. J. Chen (Contributor)



Abstract Background Children with longstanding use of antiepileptic drugs (AEDs) are susceptible to developing low bone mineral density and an increased fracture risk. However, the literature regarding the effects of AEDs on growth in epileptic children is limited. The aim of this study was to investigate the potential effects of valproate (VPA) and/or oxcarbazepine (OXC) therapy on growth velocity and bone metabolism. Methods Seventy-three ambulatory children (40 boys and 33 girls) with epilepsy, aged between 1 and 18 years (mean age 9.8 ± 4.1 years), were evaluated for growth velocity before and for 1 year after VPA and/or OXC treatment. The bone resorption marker serum tartrate-resistant acid phosphatase 5b (TRAcP5b) and the bone formation marker serum bone-specific alkaline phosphatase (BAP) were measured post-AEDs therapy for 1 year. Results The difference in growth velocity (ΔHt) and body weight change (ΔWt) between pre- and post-AEDs treatment were -1.0 ± 2.8 cm/year (P